A newly established family office based in the USA seeks to leverage its technology expertise (i.e. AI, machine learning, cloud computing, cybersecurity, etc.) and invest in innovative early-stage healthcare companies that integrate technology, has the potential to become highly disruptive, and improve quality of life. To date, the firm has invested in 3 healthcare companies and continues to grow their portfolio. Currently, the firm is focused on pre-seed to seed funding with initial check size ranging from $100-250K, and up to $1M over the lifetime of the investment. The firm has a large footprint in North America and Israel, and will consider investment opportunities globally.
The firm is most interested in companies that are developing novel solutions to healthcare through the use of technology. The firm will consider medical technology companies, given that there is a strong data or technology component. Areas of high interest include the use of AI in drug discovery, drug delivery applications, SaaS/enterprise solutions in healthcare services, etc. At this time, the firm is not interested in biotech therapeutics or B2C applications.
The firm does not have specific company or management team requirements, but having an experienced management team with a track record of success is a huge plus. The firm typically co-invests alongside larger VC firms, but is open to leading rounds as well depending on the stage of the company and the firm’s capacity to contribute as a value-add. The firm does not always seek board representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment